<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02124083</url>
  </required_header>
  <id_info>
    <org_study_id>140102</org_study_id>
    <secondary_id>14-CH-0102</secondary_id>
    <nct_id>NCT02124083</nct_id>
  </id_info>
  <brief_title>Phase 1/2 Study of Vorinostat Therapy in Niemann-Pick Disease, Type C1</brief_title>
  <official_title>Phase 1/2 Study of Vorinostat Therapy in Niemann-Pick Disease, Type C1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Niemann-Pick disease type C (NPC) is a lethal, autosomal recessive, lysosomal storage
      disorder characterized by neurodegeneration in early childhood and death in adolescence. The
      causative genes NPC1 (about 95% of cases) and NPC2 (about 5% of cases) are involved in the
      intracellular trafficking of lipids and cholesterol. Mutations on either of these genes lead
      to progressive accumulation of unesterified cholesterol and other lipids in the central
      nervous system (CNS). Vorinostat is a histone deacetylase inhibitor that has been shown in
      vivo to increase mutant NPC1 protein levels and to reverse cellular accumulation of
      unesterified cholesterol. Vorinostat has been labeled by the FDA for treatment of cutaneous
      T-cell lymphoma. In this Phase I, non-randomized, open-label, single-center study, we plan to
      study whether Vorinostat can be repurposed to treat patients with NPC1. Our primary objective
      is to determine the safety and tolerability of Vorinostat in NPC1 disease. Our secondary
      objectives will be to determine biochemical efficacy of Vorinostat to increase expression of
      NPC1 protein and normalize lipid and protein biomarkers. This study will enroll up to 12 NPC1
      patients and test the safety of two dose levels (200 and 400 mg). Drug will be administered
      on a 3 days on/4 days off schedule for 3 months at each dose level. Patients will be
      evaluated at the NIH Clinical Center at 0, 3 and 6 months. Safety will be assessed by adverse
      events (AEs), clinical laboratory tests and physical examinations. Biochemical efficacy will
      be assessed by measurement of serum and cerebral spinal fluid biomarkers. Clinical efficacy
      will be evaluated by audiologic testing, assessment ataxia, and swallowing studies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Niemann-Pick disease type C (NPC) is a lethal, autosomal recessive, lysosomal storage
      disorder characterized by neurodegeneration in early childhood and death in adolescence. The
      causative genes NPC1 (about 95% of cases) and NPC2 (about 5% of cases) are involved in the
      intracellular trafficking of lipids and cholesterol. Mutations on either of these genes lead
      to progressive accumulation of unesterified cholesterol and other lipids in the central
      nervous system (CNS). Vorinostat is a histone deacetylase inhibitor that has been shown in
      vivo to increase mutant NPC1 protein levels and to reverse cellular accumulation of
      unesterified cholesterol. Vorinostat has been labeled by the FDA for treatment of cutaneous
      T-cell lymphoma. In this Phase I, non-randomized, open-label, single-center study, we plan to
      study whether Vorinostat can be repurposed to treat patients with NPC1. Our primary objective
      is to determine the safety and tolerability of Vorinostat in NPC1 disease. Our secondary
      objectives will be to determine biochemical efficacy of Vorinostat to increase expression of
      NPC1 protein and normalize lipid and protein biomarkers. This study will enroll up to 12 NPC1
      patients and test the safety of two dose levels (200 and 400 mg). Drug will be administered
      on a 3 days on/4 days off schedule for 3 months at each dose level. Patients will be
      evaluated at the NIH Clinical Center at 0, 3 and 6 months. Safety will be assessed by adverse
      events (AEs), clinical laboratory tests and physical examinations. Biochemical efficacy will
      be assessed by measurement of serum and cerebral spinal fluid biomarkers. Clinical efficacy
      will be evaluated by audiologic testing, assessment ataxia, and swallowing studies.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 25, 2014</start_date>
  <completion_date type="Actual">December 13, 2016</completion_date>
  <primary_completion_date type="Actual">December 13, 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Tolerabilty of 200 mg Vorinostat in Niemann-Pick Disease, Type C1</measure>
    <time_frame>3 months</time_frame>
    <description>The number of Niemann-Pick Disease, type C1 patients completing 3 month 200 mg phase</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Tolerabilty of 400 mg Vorinostat in Niemann-Pick Disease, Type C1</measure>
    <time_frame>3 months</time_frame>
    <description>The number of Niemann-Pick Disease, type C1 patients completing 3 month 400 mg phase</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biochemical Efficacy as Measured by Serum Cathepsin D</measure>
    <time_frame>6 months</time_frame>
    <description>Serum concentration of Cathepsin D. Cathepsin D is an aspartyl protease involved in protein catabolism and tissue remodeling. Cathepsin D normal range = 220-515 ng/ml.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical Efficacy as Measured by Serum Cathepsin D</measure>
    <time_frame>Baseline</time_frame>
    <description>Serum concentration of Cathepsin D. Cathepsin D is an aspartyl protease involved in protein catabolism and tissue remodeling. Cathepsin D normal range = 220-515 ng/ml.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical Efficacy as Measured by Serum LGALS3</measure>
    <time_frame>6 months</time_frame>
    <description>Serum concentration of LGALS3 (galectin-3). Galectin-3 is a carbohydrate-binding lectin whose expression is associated with inflammatory cells including macrophages, neutrophils, and mast cells. LGALS3 normal range = 1.4-5.3 ng/ml.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical Efficacy as Measured by Serum LGALS3</measure>
    <time_frame>Baseline</time_frame>
    <description>Serum concentration of LGALS3 (galectin-3). Galectin-3 is a carbohydrate-binding lectin whose expression is associated with inflammatory cells including macrophages, neutrophils, and mast cells. LGALS3 normal range = 1.4-5.3 ng/ml.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Neimann-Pick Disease</condition>
  <arm_group>
    <arm_group_label>Vorinostat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Trial participants were treated with Vorinostat (3 days on/4 days off regimen) to limit toxicity. Subjects were initially dosed with 200 mg (two 100 mg capsules) by mouth daily for three months, followed by dose escalation to 400 mg (four 100 mg capsules) by mouth daily for three months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vorinostat</intervention_name>
    <description>Histone deactylase inhibitor</description>
    <arm_group_label>Vorinostat</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -INCLUSION CRITERIA:

          1. Aged greater than or equal to 18 and less than or equal to 60 years old at time of
             enrollment, either gender, and any ethnicity.

          2. Diagnosis of NPC1 based upon one of the following:

               -  Two NPC1 mutations;

               -  Positive filipin staining and at least one NPC1 mutation;

               -  Vertical supranuclear gaze palsy (VSNGP) in combination with either:

               -  One NPC1 mutation, or

               -  Positive filipin staining and no pathogenic NPC2 mutations.

          3. Patients with at least one neurological manifestation of NPC1. For example, but not
             limited to, hearing loss, vertical supranuclear gaze palsy, ataxia, dementia,
             dystonia, seizures, dysarthria, or dysphagia.

          4. A patient s cultured skin fibroblasts when treated with 10 M Vorinostat must exhibit a
             reduction in the filipin lysosomal storage organelle ratio equivalent to 75% of the
             response measured in NPC1 positive control fibroblasts.

          5. Ability to travel to the NIH Clinical Center repeatedly for evaluation and follow-up.

          6. If taking miglustat, the patient must have been taking a constant dose of the
             medication for no less than three months prior to baseline evaluation and must be
             willing to maintain that dose level for the duration of the trial.

          7. Willing to discontinue all non-prescription supplements, with the exception of an
             age-appropriate multivitamin.

          8. Women of reproductive age must be willing to use an effective method of contraception
             for the duration of the trial.

          9. Willing to participate in all aspects of trial design including serial blood and CSF
             collections.

        EXCLUSION CRITERIA:

          1. Aged below 18 or above 60 years of age at enrollment in the trial.

          2. Severe manifestations of NPC1 that would interfere with the patient s ability to
             comply with the requirements of this protocol.

          3. Neurologically asymptomatic patients.

          4. Patients who have received any form of cyclodextrin or an HDACi in an attempt to treat
             NPC1.

          5. History of hypersensitivity reactions to Vorinostat or components of the formulation.

          6. Pregnancy or breastfeeding at any time during the study.

          7. Patients with suspected infection of the CNS or any systemic infection.

          8. Neutropenia, defined as an absolute neutrophil count (ANC) of less than 1,500 per
             microliter.

          9. Thrombocytopenia defined as a platelet count less than 75,000 per microliter, or a
             history of greater than or equal to grade 2 thrombocytopenia (50,000-75,000
             platelets/microliter).

         10. Prior use of anticoagulants or history/presence of a bleeding disorder.

         11. Hepatic laboratory parameters (aspartate aminotransferase (AST), alanine
             aminotransferase, (ALT)) greater than four-times upper limit of normal.

         12. Presence of anemia defined as two standard deviations below normal for age and gender.

         13. Serum creatinine level greater than 1.5 times the upper limit of normal.

         14. Hematuria (greater than15 RBC/mcL or positive hemoglobin). This exclusion criteria
             will not apply to a female currently menstruating who has no history of renal disease
             or other evidence of renal impairment (eg hypertension, serum creatinine above upper
             limit of normal, history of renal disease). Urinalyis will be repeated after menses
             has ended and drug discontinued if hematuria persists. Efforts will be made to avoid
             menses in scheduling the initial admission.

         15. Proteinuria (1+ protein on urinalysis) Patient will not be excluded if urine
             protein/creatinine ratio is normal or if classified as benign by either patient's
             primary medical provider or upon obtaining a nephrology consult.

         16. Serum potassium or Magnesium outside of the normal laboratory range prior to
             initiation of vorinostat therapy.

         17. Diabetes or a fasting glucose greater than 106 mg/dl.

         18. Active pulmonary disease, oxygen requirement or clinically significant history of
             decreased blood oxygen saturation, pulmonary therapy, or requiring active suction.

         19. Patients with uncontrolled seizures per either of the criteria below.

               1. Unstable frequency, type or duration of seizures. Quantified by a seizure log
                  over the two months prior to enrollment.

               2. Patients requiring antiepileptic medication changes (other than dose adjustments
                  for weight) in the two months prior to enrollment, or requiring three or more
                  antiepileptic medications to control seizures.

         20. Use of another HDAC inhibitor or compounds with established HDAC inhibitory activity,
             including valproic acid, unless discontinued at least 2 months prior to enrollment.

         21. History of a thromboembolic event (such as DVT or Pulmonary embolism).

         22. Patients, who in the opinion of the investigators, are unable to comply with the
             protocol or have specific health concerns that would potentially increase the risk of
             participation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Forbes D Porter, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2014-CH-0102.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Vanier MT. Niemann-Pick diseases. Handb Clin Neurol. 2013;113:1717-21. doi: 10.1016/B978-0-444-59565-2.00041-1. Review.</citation>
    <PMID>23622394</PMID>
  </reference>
  <reference>
    <citation>Ory DS. Niemann-Pick type C: a disorder of cellular cholesterol trafficking. Biochim Biophys Acta. 2000 Dec 15;1529(1-3):331-9. Review.</citation>
    <PMID>11111100</PMID>
  </reference>
  <reference>
    <citation>SÃ©vin M, Lesca G, Baumann N, Millat G, Lyon-Caen O, Vanier MT, Sedel F. The adult form of Niemann-Pick disease type C. Brain. 2007 Jan;130(Pt 1):120-33. Epub 2006 Sep 26. Review.</citation>
    <PMID>17003072</PMID>
  </reference>
  <verification_date>January 13, 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 25, 2014</study_first_submitted>
  <study_first_submitted_qc>April 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2014</study_first_posted>
  <results_first_submitted>December 12, 2017</results_first_submitted>
  <results_first_submitted_qc>January 24, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">February 22, 2018</results_first_posted>
  <last_update_submitted>January 24, 2018</last_update_submitted>
  <last_update_submitted_qc>January 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Niemann Pick Disease, Type C1</keyword>
  <keyword>Phase I, Phase 2</keyword>
  <keyword>Vorinostat</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pick Disease of the Brain</mesh_term>
    <mesh_term>Aphasia, Primary Progressive</mesh_term>
    <mesh_term>Frontotemporal Dementia</mesh_term>
    <mesh_term>Niemann-Pick Diseases</mesh_term>
    <mesh_term>Niemann-Pick Disease, Type A</mesh_term>
    <mesh_term>Niemann-Pick Disease, Type C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vorinostat</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Vorinostat</title>
          <description>Trial participants were treated with Vorinostat (3 days on/4 days off regimen) to limit toxicity. Subjects were initially dosed with 200 mg (two 100 mg capsules) by mouth daily for three months, followed by dose escalation to 400 mg (four 100 mg capsules) by mouth daily for three months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Vorinostat</title>
          <description>Trial participants were treated with Vorinostat (3 days on/4 days off regimen) to limit toxicity. Subjects were initially dosed with 200 mg (two 100 mg capsules) by mouth daily for three months, followed by dose escalation to 400 mg (four 100 mg capsules) by mouth daily for three months.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Biochemical Efficacy as Measured by Serum Cathepsin D</title>
        <description>Serum concentration of Cathepsin D. Cathepsin D is an aspartyl protease involved in protein catabolism and tissue remodeling. Cathepsin D normal range = 220-515 ng/ml.</description>
        <time_frame>6 months</time_frame>
        <population>All participants completing both 200 and 400 mg phases</population>
        <group_list>
          <group group_id="O1">
            <title>Vorinostat</title>
            <description>Trial participants were treated with Vorinostat (3 days on/4 days off regimen) to limit toxicity. Subjects were initially dosed with 200 mg (two 100 mg capsules) by mouth daily for three months, followed by dose escalation to 400 mg (four 100 mg capsules) by mouth daily for three months.</description>
          </group>
        </group_list>
        <measure>
          <title>Biochemical Efficacy as Measured by Serum Cathepsin D</title>
          <description>Serum concentration of Cathepsin D. Cathepsin D is an aspartyl protease involved in protein catabolism and tissue remodeling. Cathepsin D normal range = 220-515 ng/ml.</description>
          <population>All participants completing both 200 and 400 mg phases</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="625.3" spread="183.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Biochemical Efficacy as Measured by Serum Cathepsin D</title>
        <description>Serum concentration of Cathepsin D. Cathepsin D is an aspartyl protease involved in protein catabolism and tissue remodeling. Cathepsin D normal range = 220-515 ng/ml.</description>
        <time_frame>Baseline</time_frame>
        <population>All participants who started study</population>
        <group_list>
          <group group_id="O1">
            <title>Vorinostat</title>
            <description>Trial participants were treated with Vorinostat (3 days on/4 days off regimen) to limit toxicity. Subjects were initially dosed with 200 mg (two 100 mg capsules) by mouth daily for three months, followed by dose escalation to 400 mg (four 100 mg capsules) by mouth daily for three months.</description>
          </group>
        </group_list>
        <measure>
          <title>Biochemical Efficacy as Measured by Serum Cathepsin D</title>
          <description>Serum concentration of Cathepsin D. Cathepsin D is an aspartyl protease involved in protein catabolism and tissue remodeling. Cathepsin D normal range = 220-515 ng/ml.</description>
          <population>All participants who started study</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="648.2" spread="266"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Biochemical Efficacy as Measured by Serum LGALS3</title>
        <description>Serum concentration of LGALS3 (galectin-3). Galectin-3 is a carbohydrate-binding lectin whose expression is associated with inflammatory cells including macrophages, neutrophils, and mast cells. LGALS3 normal range = 1.4-5.3 ng/ml.</description>
        <time_frame>6 months</time_frame>
        <population>All participants completing both 200 and 400 mg phases</population>
        <group_list>
          <group group_id="O1">
            <title>Vorinostat</title>
            <description>Trial participants were treated with Vorinostat (3 days on/4 days off regimen) to limit toxicity. Subjects were initially dosed with 200 mg (two 100 mg capsules) by mouth daily for three months, followed by dose escalation to 400 mg (four 100 mg capsules) by mouth daily for three months.</description>
          </group>
        </group_list>
        <measure>
          <title>Biochemical Efficacy as Measured by Serum LGALS3</title>
          <description>Serum concentration of LGALS3 (galectin-3). Galectin-3 is a carbohydrate-binding lectin whose expression is associated with inflammatory cells including macrophages, neutrophils, and mast cells. LGALS3 normal range = 1.4-5.3 ng/ml.</description>
          <population>All participants completing both 200 and 400 mg phases</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.565" spread="4.775"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Biochemical Efficacy as Measured by Serum LGALS3</title>
        <description>Serum concentration of LGALS3 (galectin-3). Galectin-3 is a carbohydrate-binding lectin whose expression is associated with inflammatory cells including macrophages, neutrophils, and mast cells. LGALS3 normal range = 1.4-5.3 ng/ml.</description>
        <time_frame>Baseline</time_frame>
        <population>All participants who started study</population>
        <group_list>
          <group group_id="O1">
            <title>Vorinostat</title>
            <description>Trial participants were treated with Vorinostat (3 days on/4 days off regimen) to limit toxicity. Subjects were initially dosed with 200 mg (two 100 mg capsules) by mouth daily for three months, followed by dose escalation to 400 mg (four 100 mg capsules) by mouth daily for three months.</description>
          </group>
        </group_list>
        <measure>
          <title>Biochemical Efficacy as Measured by Serum LGALS3</title>
          <description>Serum concentration of LGALS3 (galectin-3). Galectin-3 is a carbohydrate-binding lectin whose expression is associated with inflammatory cells including macrophages, neutrophils, and mast cells. LGALS3 normal range = 1.4-5.3 ng/ml.</description>
          <population>All participants who started study</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.667" spread="2.303"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Tolerabilty of 200 mg Vorinostat in Niemann-Pick Disease, Type C1</title>
        <description>The number of Niemann-Pick Disease, type C1 patients completing 3 month 200 mg phase</description>
        <time_frame>3 months</time_frame>
        <population>All participants who started study</population>
        <group_list>
          <group group_id="O1">
            <title>Vorinostat</title>
            <description>Trial participants were treated with Vorinostat (3 days on/4 days off regimen) to limit toxicity. Subjects were initially dosed with 200 mg (two 100 mg capsules) by mouth daily for three months, followed by dose escalation to 400 mg (four 100 mg capsules) by mouth daily for three months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Tolerabilty of 200 mg Vorinostat in Niemann-Pick Disease, Type C1</title>
          <description>The number of Niemann-Pick Disease, type C1 patients completing 3 month 200 mg phase</description>
          <population>All participants who started study</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Tolerabilty of 400 mg Vorinostat in Niemann-Pick Disease, Type C1</title>
        <description>The number of Niemann-Pick Disease, type C1 patients completing 3 month 400 mg phase</description>
        <time_frame>3 months</time_frame>
        <population>All participants completing 200 mg phase and starting 400 mg phase</population>
        <group_list>
          <group group_id="O1">
            <title>Vorinostat</title>
            <description>Trial participants were treated with Vorinostat (3 days on/4 days off regimen) to limit toxicity. Subjects were initially dosed with 200 mg (two 100 mg capsules) by mouth daily for three months, followed by dose escalation to 400 mg (four 100 mg capsules) by mouth daily for three months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Tolerabilty of 400 mg Vorinostat in Niemann-Pick Disease, Type C1</title>
          <description>The number of Niemann-Pick Disease, type C1 patients completing 3 month 400 mg phase</description>
          <population>All participants completing 200 mg phase and starting 400 mg phase</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Vorinostat</title>
          <description>Trial participants were treated with Vorinostat (3 days on/4 days off regimen) to limit toxicity. Subjects were initially dosed with 200 mg (two 100 mg capsules) by mouth daily for three months, followed by dose escalation to 400 mg (four 100 mg capsules) by mouth daily for three months.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Epstein-Barr viraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Cerebrospinal fluid leakage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Liver function test increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tympanic membrane perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Gastrostomy tube site complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Reflux gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Salivary hypersecretion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Lip infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Liver function test increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Cataplexy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Mania</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Personality change</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Tracheostomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Porter, Forbes</name_or_title>
      <organization>National Institute of Child Health and Human Development</organization>
      <phone>+1 301 435 4432</phone>
      <email>fdporter@mail.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

